Multicenter_study_of_superficial_bladder_cancer_treated_with_intravesical_bacillus_Calmette-Guerin_or_adriamycin._Results_of_long-term_follow-up._We_evaluated_158_cases_of_patients_with_superficial_bladder_cancers_(Stages_Ta,_T1,_and_Tis)._These_cases_were_treated_with_either_intravesical_bacillus_Calmette-Guerin_(BCG)_(Tice_strain)_or_Adriamycin_(ADR),_in_a_multicenter,_nonrandomized_study._One_hundred_thirty-one_of_these_patients_were_followed_up;_the_results_continue_to_show_a_higher_percentage_of_initial_complete_remissions_with_BCG_(68%)_than_with_ADR_(57%)._With_additional_therapy,_both_BCG_and_ADR_achieved_complete_remission_in_83_percent_of_the_patients._When_7_failures_with_patients_taking_ADR_were_switched_to_BCG_and_the_disease_cleared,_the_rate_of_complete_remission_for_BCG_rose_to_85_percent._The_recurrence_rate_per_100_patient-months_was_only_slightly_different_for_BCG_(0.9)_and_ADR_(0.8)._The_percentage_of_progressions_continued_to_be_higher_for_BCG_(8%)_than_for_ADR_(5%)._Cystectomies_were_performed_in_2.5_percent_of_the_BCG_patients._Using_the_Cox_regression_model_with_covariates,_we_found_drug_treatment,_tumor_grade,_and_sex_to_be_statistically_significant_in_determining_failures_throughout_the_protocol._Although_both_BCG_and_ADR_were_effective_over_the_course_of_the_study,_BCG_is_the_drug_of_choice_for_residual_tumor_(Stages_T1_and_Tis).